New insights into carnitine‐acylcarnitine translocase deficiency from 23 cases: Management challenges and potential therapeutic approaches
- 26 February 2021
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (4), 903-915
- https://doi.org/10.1002/jimd.12371
Abstract
Background Carnitine acyl‐carnitine translocase deficiency (CACTD) is a rare autosomal recessive disorder of mitochondrial long‐chain fatty‐acid transport. Most patients present in the first two days of life, with hypoketotic hypoglycaemia, hyperammonaemia, cardiomyopathy or arrhythmia, hepatomegaly and elevated liver enzymes. Method Multi‐centre international retrospective chart review of clinical presentation, biochemistry, treatment modalities including diet, subsequent complications, and mode of death of all patients. Results Twenty‐three patients from nine tertiary metabolic units were identified. Seven attenuated patients of Pakistani heritage, 6 of these homozygous c.82G>T, had later onset manifestations and long‐term survival without chronic hyperammonemia. Of the sixteen classical cases, fifteen had cardiac involvement at presentation comprising cardiac arrhythmias (9/15), cardiac arrest (7/15) and cardiac hypertrophy (9/15). Where recorded, ammonia levels were elevated in all but one severe case (13/14 measured) and 14/16 had hypoglycaemia. Nine classical patients survived longer‐term – most with feeding difficulties and cognitive delay. Hyperammonaemia appears refractory to ammonia scavenger treatment and carglumic acid, but responds well to high glucose delivery during acute metabolic crises. High‐energy intake seems necessary to prevent decompensation. Anaplerosis utilizing therapeutic D,L‐3‐hydroxybutyrate, Triheptanoin and increased protein intake, appeared to improve chronic hyperammonemia and metabolic stability where trialled in individual cases. Conclusion CACTD is a rare disorder of fatty acid oxidation with a preponderance to severe cardiac dysfunction. Long‐term survival is possible in classical early‐onset cases with long‐chain fat restriction, judicious use of glucose infusions, and medium chain triglyceride supplementation. Adjunctive therapies supporting anaplerosis may improve longer‐term outcomes.This publication has 42 references indexed in Scilit:
- Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD−/−) Mouse to Compensate a Defective Fatty Acid β-OxidationPLOS ONE, 2012
- Expanded molecular features of carnitine acyl-carnitine translocase (CACT) deficiency by comprehensive molecular analysisMolecular Genetics and Metabolism, 2011
- A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiencyMolecular Genetics and Metabolism, 2009
- Disorders of carnitine transport and the carnitine cycleSeminars in Medical Genetics, Part C of the American Journal of Medical Genetics, 2006
- Carnitine?acylcarnitine translocase deficiency, clinical, biochemical and genetic aspectsMolecular Aspects of Medicine, 2004
- Molecular and functional analysis ofSLC25A20 mutations causing carnitine-acylcarnitine translocase deficiencyHuman Mutation, 2004
- Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolismMolecular Genetics and Metabolism, 2004
- Aberrant mRNA Splicing Associated with Coding Region Mutations in Children with Carnitine-Acylcarnitine Translocase DeficiencyMolecular Genetics and Metabolism, 2001
- Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocaseThe Journal of Pediatrics, 1995
- Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts.JCI Insight, 1993